Candida FKS gene mutations attenuate echinocandin activity, but overall mutation rates among clinical isolates remain low (Candida glabrata, $4%; other species, <1%). Rates are higher with prior echinocandin exposure, exceeding 50% among C. glabrata or Candida albicans isolates causing breakthrough invasive candidiasis. The median duration of prior echinocandin exposure among FKS mutant isolates is $100 days. The clinical usefulness of echinocandin susceptibility testing is limited by the low overall prevalence of resistance, and uncertainties surrounding testing methods and interpretation of minimum inhibitory concentrations (MICs). In single-center studies, caspofungin resistance (defined using institution-specific MIC breakpoints) was 32-53% sensitive and 75-95% specific for predicting treatment outcomes of C. glabrata invasive candidiasis; corresponding values for the presence of an FKS mutation were 35-41% and 90-98%. Results were similar using anidulafungin and micafungin MICs. Clinical data are scarce for non-C. glabrata species.
INTRODUCTION
Echinocandin antifungals (anidulafungin, caspofungin and micafungin) are the agents of choice for the treatment of invasive candidiasis [1] [2] [3] . The drugs exert fungicidal activity against Candida species in vitro by inhibiting the synthesis of b-1,3-Dglucan, a major cell wall constituent [4] . Although there are some pharmacokinetic differences among the agents, practice guidelines consider the echinocandins to be interchangeable [1, 2] .
Widespread echinocandin usage has been accompanied by reports of emerging drug resistance among clinical Candida isolates, particularly among the haploid species Candida glabrata [5, 6] . Although these reports are worrisome, uncertainty surrounds the extent and clinical significance of echinocandinresistant Candida. Moreover, methods for detecting resistance, the roles of resistance testing in clinical practice and the impact of emerging resistance on the management of invasive candidiasis are unclear. In this article, we review echinocandin resistance among Candida species and offer our clinical perspectives on the phenomenon.
FKS MUTATIONS AMONG CANDIDA SPECIES
The catalytic subunit of the echinocandin target enzyme, b-1,3-D-glucan synthase, is encoded by FKS1, FKS2 and FKS3 genes. Mutations in hot spot regions of FKS1 (all Candida species) or FKS2 (C. glabrata) result in amino acid substitutions that attenuate echinocandin activity [7 && ]. Echinocandin inhibition of b-1,3-D-glucan synthase is reduced by 30-fold to several thousand-fold in isolates harboring FKS mutations [8] [9] [10] . Readers interested in the impact of specific FKS mutations on echinocandin susceptibility are referred to a recent review [7 && ].
Five Candida species account for more than 95% of invasive candidiasis. Among these species, Candida albicans, C. glabrata, Candida tropicalis and Candida krusei can acquire FKS mutations under selection pressure. Certain acquired FKS mutations result in highly-attenuated susceptibility in vitro, which correlates with poor treatment responses in mouse models of disseminated candidiasis [7 && ,8,9,11-13,14 & ]. Candida parapsilosis, in contrast, harbors a naturally occurring FKS1 polymorphism that confers diminished echinocandin susceptibility [10] , the clinical significance of which is not established [15] [16] [17] .
The prevalence of FKS mutant Candida is not precisely defined (Table 1) [5, 18, 19 && ,20-22,23 && , 24 && , [25] [26] [27] [28] . Reported rates of 8-18% among C. glabrata isolates at certain high-risk centers may overstate prevalence as studies have been limited by incomplete access to medical records and/or a lack of systematic testing across consecutive isolates [5,19 && ,20] . In a more recent study of 453 ]. These low rates are in general agreement with data from international repositories [18,30 & ,31] . FKS mutant C. tropicalis and C. krusei have been described in case reports [22,24 && ,25-28], but rates among repository strains are low [18] .
It is important to understand that FKS mutations arise in specific clinical settings, within which echinocandin resistance rates are significantly higher than in the broader population with invasive candidiasis. Most notably, FKS mutant C. glabrata and C. albicans are recovered almost exclusively from patients with prior echinocandin exposure [5,19 && ,20,21] . The greatest risk is among patients who develop breakthrough infections during treatment, in whom at least 50% of C. glabrata or C. albicans isolates harbor mutations (Table 1 ) [22, 32] . In contrast, FKS mutant isolates account for less than 10% of C. glabrata or C. albicans infections among patients with remote echinocandin exposure [29 && ]; risk is greatest for exposure within the preceding month [19 && ]. In both breakthrough and remote settings, prolonged echinocandin exposure is typically required for the emergence of mutations (median: $100 days; range: 7-450 days) [20, 21, 29 && ,32]. By the same token, infections by wild-type C. glabrata have been reported after as many as 84 treatment days [21,22, 
ECHINOCANDIN SUSCEPTIBILITY TESTING
At present, most hospital microbiology laboratories do not have the capacity to detect FKS mutations
KEY POINTS
Mutations in hot spot regions of FKS genes lead to decreased echinocandin susceptibility among Candida species, but they remain uncommon outside of C. glabrata or C. albicans isolates recovered from patients with breakthrough infections or extensive drug exposure in the recent past.
The clinical utility of echinocandin MIC measurements is limited by the low overall prevalence of resistant Candida isolates, and uncertainties about optimal testing methods, interlaboratory reproducibility (particularly for caspofungin), resistance breakpoints and correlations with responses to echinocandin treatment among patients with invasive candidiasis.
Most echinocandin treatment failures for invasive candidiasis are not because of drug resistance, but rather a combination of factors such as underlying disease, host immune function, severity of illness, source control, time to initiation of treatment, pharmacokinetic-pharmacodynamic parameters and isolate fitness.
Either an elevated echinocandin MIC or the detection of an FKS mutation may predict treatment failures among patients with invasive candidiasis due to C. glabrata, but the roles of genotypic or phenotypic testing in clinical practice are undefined.
Echinocandins remain preferred agents against the vast majority of invasive Candida infections, and susceptibility testing and/or screening for FKS mutations is best reserved for echinocandin-experienced patients with newly diagnosed infections or those who have not responded to echinocandin treatment. [35] [36] [37] . Echinocandin susceptibility is typically assessed by measuring minimum inhibitory concentrations (MICs), and comparing results to interpretive clinical breakpoints. Reference broth microdilution methods for testing echinocandins against Candida species have been developed by the Clinical Laboratory Standards Institute (CLSI) [38] and European Committee on Antimicrobial Susceptibility Testing (EUCAST) [39] . Drug-specific and species-specific breakpoints have been derived from data on MIC distributions, pharmacokineticpharmacodynamic (PK-PD) parameters, epidemiological cut-off values (ECVs), and, to a lesser extent, patient responses to echinocandin treatment (Table  2) [40, 41] . MICs and clinical breakpoints are higher for C. parapsilosis than other species, in keeping with intrinsic FKS polymorphisms. A prominent limitation of echinocandin susceptibility testing is that CLSI and EUCAST clinical breakpoints often differ. Discrepancies in clinical breakpoints are one of the several major issues that make the interpretation of echinocandin MICs difficult in the clinic.
Shortly after the CLSI proposed interpretive criteria, it became apparent that caspofungin MICs varied significantly among laboratories using broth microdilution methods. Results of a large international study showed that modal caspofungin MICs generated in individual laboratories by either of the reference methods differed by at least four two-fold dilutions against C. albicans, C. glabrata, C. tropicalis and C. krusei [42] . In contrast, modal anidulafungin and micafungin MICs were distributed within narrow ranges. Given these data, EUCAST has not proposed caspofungin breakpoints, and recommends against testing this agent [41, 43] . Variability in caspofungin MICs is most relevant for C. glabrata, as rates of nonsusceptibility approach 100% at some centers applying CLSI breakpoints [20, 44] .
The overall clinical impact of caspofungin MIC variability is somewhat mitigated by the fact that an overwhelming majority of hospitals do not use reference broth microdilution methods, but rather commercialized assays such as Sensititre YeastOne (SYO, Trek Diagnostics, Cleveland, Ohio, USA) and Etest (Biomerieux, Marcy-I'Etoile, France), or automated systems like Vitek 2 (Biomerieux) [45 && ,46] . Echinocandin MICs generated by these methods and reference methods demonstrate good essential agreement (MICs within a two-fold dilution), but categorical agreement (defining isolates as susceptible, intermediate or resistant) using reference breakpoints may be lower [47, 48] . In a recent study of hospitals that routinely perform susceptibility testing, interlaboratory modal echinocandin MICs obtained by SYO (including those of caspofungin) were within a single two-fold dilution against each Candida species [45 && ]. However, the use of CLSI breakpoints resulted in disproportionately high rates of caspofungin nonsusceptibility among C. glabrata and C. krusei, compared with other agents. In a follow-up study at one of the hospitals, FKS mutations were not detected among isolates that were nonsusceptible to caspofungin but susceptible to other agents [29 && ]. Therefore, commercialized assays like SYO may reduce the interlaboratory variation in caspofungin MICs seen with reference methods; at the same time, CLSI and EUCAST interpretive criteria may not be valid in classifying MICs generated by these assays, particularly for caspofungin.
The distinction between clinical breakpoints and ECVs is another issue of confusion for many clinicians. Clinical breakpoints assign MICs at which the likelihood of treatment failure is increased, and thus they are designed to predict patient outcomes. An ECV, on the other hand, distinguishes between a population of wild-type, drug-susceptible isolates and a population that includes nonwild-type isolates with acquired resistance mechanisms. To this end, the ECV is designed to be a sensitive surveillance tool for detecting In fact, correlations between echinocandin MICs and treatment responses remain uncertain. In a comprehensive investigation of 746 Candida isolates from six caspofungin treatment studies for esophageal (four trials; 515 isolates) or invasive candidiasis (two trials; 231 isolates), there was no correlation between caspofungin MICs (as determined by broth microdilution) and patient outcomes [44] . Upon closer consideration, these results are not necessarily surprising as studies did not include patients with prior echinocandin exposure. Indeed, the absence of associations between MICs and outcomes in patients at low-risk for resistance highlights that microbiologic resistance is not the sole determinant of treatment response. For invasive candidiasis, factors such as underlying disease, host immune function, severity of illness, source control, time to initiation of treatment, PK-PD parameters and isolate fitness may play more significant roles in a given patient than antifungal susceptibility [51] . Studies seeking to demonstrate correlations between echinocandin MICs and outcomes should include patients from highrisk populations in which resistance is most likely to emerge.
ECHINOCANDIN MINIMUM INHIBITORY CONCENTRATIONS, FKS MUTATIONS AND TREATMENT OUTCOMES
Several single-center studies have investigated MICs and FKS mutations as potential risk factors for echinocandin treatment failures among patients with invasive candidiasis. At three centers using various testing methods and either CLSI or institutionspecific, receiver operator characteristic (ROC)derived breakpoints, treatment failure rates among patients with invasive infections due to caspofungin-resistant or FKS mutant C. glabrata were 47-79% and 60-90%, respectively (Table 3) [41] , but they are not presented here to maintain clarity. [5,19 && ,20,21,52] . Caspofungin resistance was 32-53% sensitive (percentage of patients in whom treatment failed who were infected with resistant isolates) and 75-95% specific (percentage of patients in whom treatment was successful who were infected with nonresistant isolates). The corresponding sensitivity and specificity for the presence of an FKS mutation were 35-41% and 90-98%, respectively [5,19 && ,20,21] . In a study of cancer patients with C. glabrata candidemia that did not assess FKS mutations, caspofungin MICs determined by CLSI broth microdilution were inversely related to 28-day all-cause mortality (P ¼ 0.001); mortality rates among patients infected with resistant and nonresistant C. glabrata isolates by CLSI breakpoints were 57% (8 of 14) and 28% (22 of 79), respectively [34 && ]. Caspofungin resistance or the presence of an FKS mutation was an independent risk factor for treatment failure in some, but not all of these studies [5, 19 && ,20,21,34 && ,53 && ]. Prior echinocandin exposure likewise was associated with unsuccessful treatment of invasive C. glabrata infections in several studies [5, 20] , and implicated as an independent risk factor in one study [19 && ]. Echinocandin exposure, FKS mutations and phenotypic resistance are interrelated factors, which complicates the assessment of their relative contributions to outcomes. An elevated MIC in the setting of prior echinocandin exposure was a useful surrogate for the detection of FKS mutations among C. glabrata isolates at one center, and an algorithm that considered these factors accurately predicted treatment responses (Fig. 1) [21, 52] .
Data are limited for infections due to species other than C. glabrata, and for associations between anidulafungin and micafungin MICs and treatment responses. Elevated echinocandin MICs and FKS mutations among C. albicans, C. krusei, and C. tropicalis isolates have been linked to unsuccessful therapy in individual cases [22,24 && ,54-57] . In clinical trials, outcomes among patients treated with echinocandins for C. parapsilosis candidemia have not been impaired, despite higher MICs and intrinsic FKS polymorphisms [15] [16] [17] ; conclusive data on deep-seated C. parapsilosis infections such as endocarditis are lacking. An association was demonstrated between caspofungin resistance, as determined by broth microdilution and CLSI breakpoints, and excess mortality among cancer patients with candidemia due to non-C. albicans species [53 && ]; however, these findings were based largely on resistant C. glabrata. In another study that used CLSI broth microdilution methods and clinical breakpoints, anidulafungin and micafungin MICs were superior to caspofungin MICs in predicting caspofungin treatment outcomes among patients with invasive C. glabrata infections [52] . Of note, ROC-derived breakpoints for anidulafungin and micafungin performed better than CLSI breakpoints. Moreover, ROC-derived caspofungin breakpoints performed comparably with ROC-derived anidulafungin and micafungin breakpoints. For For the subset of patients with echinocandinbreakthrough invasive candidiasis or infections following prolonged, remote drug exposure, a practical approach is to treat with an agent from an antifungal class for which the patient is treatment-naive. This strategy is infeasible in a growing minority of echinocandin-experienced patients who have prior exposure to multiple antifungals. In such patients or in those with invasive candidiasis who do not respond to echinocandin treatment, susceptibility testing or FKS genotyping may be useful. At present, it is unclear whether echinocandin MICs or FKS genotypes correlate more closely with treatment responses. Given uncertainties about susceptibility testing methods and precise clinical breakpoints, FKS mutations are easier to interpret; however, most hospital laboratories are not equipped to perform genotypic testing. An elevated echinocandin MIC in the context of prior drug exposure may be a useful proxy for the presence of an FKS mutation. 
CONCLUSION
Echinocandin resistance among Candida species has emerged, and the challenges it poses to clinicians are likely to become more pronounced. As clinicians grapple with the issue, several questions merit immediate research investigation ( Table 4 ). The emergence of echinocandin resistance has stemmed directly from the extensive use of these agents. Therefore, strict antifungal stewardship is the most powerful weapon for preserving echinocandin susceptibility. What are the roles of echinocandin susceptibility testing and screening for FKS gene mutations in clinical practice?
What mechanisms other than FKS mutations mediate echinocandin resistance among Candida species?
Are there clinically meaningful differences between echinocandins, such as agent-specific resistance mechanisms and site-specific pharmacokinetics?
Can antifungal stewardship programs limit the emergence of echinocandin-resistant Candida?
Can rapid diagnostics and molecular resistance markers be incorporated into rational patient management strategies?
MIC, minimum inhibitory concentration.
